This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1442 entries already.
Munich-based Innovative Molecules steps into the spotlight with a partnership with Italy’s Alfasigma. The deal brings fresh capital and a global licence for adibelivir, a next-generation antiviral targeting the ultra-rare, life-threatening Herpes Simplex Virus (HSV) encephalitis.
Fresenius Kabi and TQ Therapeutics have entered into a strategic development agreement in cell and gene therapy. Fresenius Kabi receives an exclusive licence to develop, manufacture and distribute products incorporating TQ’s cell selection technology. The aim is to enable more scalable, efficient cell therapy production and broader, more cost-effective patient access.
For BioNTech, 2026 could become one of the most decisive years since its pandemic-driven breakthrough. The pipeline is broad, the coffers are well stocked, partnerships are numerous, and the outlook extends far beyond 2030. Yet despite all the strategic preparation, one key question will be answered in the coming months: can the clinical data live up to the high expectations surrounding BioNTech’s cancer strategy?
While much of the biotech industry is focused on meetings and dealmaking at the J.P. Morgan (JPM) Healthcare Conference, a rumor has cut through the JPM noise. The possibility of Eli Lilly making a move on Abivax is back on the table, with a price tag that would imply a valuation close to twice the French company’s current market capitalisation at €8.4 billion ($9.8 billion).
bit.bio has raised $50 million in a series C round led by M&G Investments to support the next phase of its human cell programming business. The Cambridge-based company develops defined human cells using its opti-ox technology, supplying reproducible cell types to researchers and drug developers for use in drug discovery.
Roche is back in China — and this time at a very different price point. In a renewed partnership with MediLink Therapeutics, the Swiss pharmaceutical group has secured a second antibody–drug conjugate (ADC), underlining how the first collaboration has paid dividends for both sides.
Just over a year and a half ago, Swiss biotech Numab AG, based in Horgen on Lake Zurich, made the headlines when it sold a single antibody to Johnson & Johnson for US$1.25 billion via a spin-out vehicle. No back-loaded milestones, no future contingencies — but cash up front, as one might say, straight into the pocket.
Patent disputes are part of everyday life in pharma. What is unusual is the timing. More than three years after the peak of the Covid-19 pandemic, Bayer has launched a broad patent offensive against the makers of mRNA vaccines – just as the market has cooled and the pandemic feels firmly in the rear-view mirror. Understandable from a financial perspective, perhaps, but still raising questions about the timing.
Paris-based start-up Enodia Therapeutics has secured €20.7 million in seed funding to advance its early-stage pipeline of targeted protein degradation. Elaia, Pfizer Ventures and Bpifrance led the Seed financing under the InnoBio investment framework, with further contributions from Wallonie Entreprendre, Argobio Studio, MACSF, the Institut Pasteur, InvestSud, Sambrinvest and Mission BioCapital.
Paris-based private equity firm Andera Partners has kicked off 2026 with a surge of cross-border activity, leading two significant Series A financings for U.S. life sciences ventures. The back-to-back rounds of the French investment fund signal a commitment to innovative startups in the United States, where both companies are headquartered and conducting key development operations